On May 8, BeiGene officially released its Q1 2026 financial results. Against the backdrop of overall pressure on China's innovative drug industry and increasingly intense competition in R&D and commercialization, the company's revenue performance bucked the trend and exceeded market expectations. Even more striking and industry-shaking, the company simultaneously announced a major pipeline strategy adjustment — terminating six investigational programs at once, covering five hot oncology targets and one autoimmune disease pipeline, signaling a clear strategic retrenchment. This "amputation-style" strategic adjustment marks the official end of China's innovative drug leader's past "land-grab" expansion model, fully transitioning to a new stage of high-quality development centered on "precision focus, efficient investment, and quality first," setting a benchmark for industry transformation.

I. Core Products Continue to Drive Growth, Commercialization Capabilities Re-validated
Key financial data shows that in Q1 2026, BeiGene's global product revenue reached US$1.5 billion, a substantial 34% year-over-year increase, demonstrating strong and steady growth momentum that fully reflects its mature commercial structure and the market competitiveness of its core products. The flagship product Zanubrutinib continued to play its "anchor" role, with global sales reaching US$1.1 billion in Q1, up 38% year-over-year. The U.S. market contributed US$761 million, up 35% year-over-year, with market penetration continuing to rise and hitting a new all-time high. Based on this strong performance, the company set its 2026 full-year total revenue guidance at US$6.3–6.5 billion, demonstrating confidence in future growth. Another core product, Tislelizumab, performed steadily, with global sales of US$206 million in Q1, up 20% year-over-year. Notably, its marketing application in combination with Zenidatamab and chemotherapy for first-line treatment of HER2-positive gastroesophageal adenocarcinoma has been accepted by the U.S. FDA and granted Priority Review status. This combination regimen has shown significant overall survival benefits in clinical studies and is expected to further expand the product's market potential. Additionally, Amgen-licensed products continued to generate synergies, with Q1 sales of US$142 million, up 25% year-over-year, serving as an important supplement to the company's global revenue and diversifying its revenue structure.
II. Hot Indications Cool Down — Industry Logic Behind the Termination of 6 Major Programs
The six terminated programs cover multiple popular oncology targets including EGFR and Pan-KRAS, involving major disease areas with significant clinical need such as lung cancer and breast cancer. Behind the seemingly "aggressive" adjustment lies a rational judgment based on industry trends, market competition, and the company's own development strategy, embodying clear industry logic.
Lung Cancer Track: Timely Loss Mitigation in a Red-Ocean Market
As BeiGene's long-term core focus area, two lung cancer-related programs were terminated. The primary reason is rational contraction after fierce competition. For the EGFR-targeting BG-60366, the market has entered a red-ocean landscape — third-generation EGFR-TKIs already dominate, while fourth-generation product development is white-hot, creating enormous competitive pressure and market barriers for late entrants. Terminating this program is rational loss mitigation to avoid resource waste. The pan-KRAS inhibitor BGB-53038 was also terminated. Although this target has long attracted industry attention, its development has consistently faced core technical bottlenecks — how to broadly target tumor cells while effectively controlling toxicity to normal cells — for which the industry has yet to develop mature solutions, making program advancement highly risky.
Frontier Areas: Strategic Contraction in High-Risk Tracks
In innovative frontier areas such as synthetic lethality and cell cycle regulation, BeiGene proactively made strategic contractions to focus on more promising core directions. The MAT2A inhibitor BG-89894, in-licensed from CSPC Pharmaceutical Group, did not demonstrate sufficient differentiation advantage or clinical application potential in preclinical and early clinical data, failing to meet the company's internal program priority standards. Terminating this program aligns with resource allocation optimization. The CDK2 inhibitor BG-68501, in-licensed from Ansheng Pharma, faced rapidly accelerating development of similar drugs by multinational giants, intensifying market competition and significantly compressing future commercial potential, ultimately being included in the termination scope.
Most Surprising Termination: PROTAC Technology Encounters Commercialization Challenges
Among the terminated programs, the Phase II-stage IRAK4 degrader BGB-45035 is the most surprising. As a representative product of PROTAC technology, it theoretically offers significant therapeutic advantages and was once highly anticipated by the market. However, from a market reality perspective, the rheumatoid arthritis treatment market has entered a mature phase, with TNF-α inhibitors and other traditional drugs holding dominant market share. Meanwhile, IRAK4-related products under development globally all face dual challenges of safety and efficacy, with unclear commercialization prospects. BeiGene's timely loss mitigation at Phase II effectively avoids greater subsequent R&D investment and market risk.
III. Proactive Restructuring: Focusing on Core Strengths for the Next Phase of Innovation
This major pipeline adjustment is not passive contraction but a proactive choice based on deep consideration of industry trends and the company's own development strategy, demonstrating strategic resolve and a pragmatic approach. Currently, the innovative drug industry has entered a period of deep adjustment, with continuously rising R&D costs and increasing pressure from medical insurance payment controls. Me-too drugs lacking differentiation have gradually lost market viability, and precision innovation has become the core trend in industry development. Looking back at the industry expansion period, BeiGene had rapidly built up its pipeline through external in-licensing. However, some externally partnered assets were of uneven quality and lacked alignment with the company's core development direction. Among the six terminated programs, several were early-stage external collaboration assets, making this adjustment an optimization of past pipeline structure. By terminating early-stage programs with intense competition and insufficient differentiation, BeiGene can concentrate its limited R&D and financial resources on core competitive products such as Zanubrutinib and Tislelizumab, as well as investigational programs with greater clinical value and differentiation potential, maximizing resource utilization efficiency. To date, BeiGene still has 18 new molecular entities in its pipeline, broadly covering core therapeutic areas including lung cancer, breast cancer, and hematological malignancies, with no weakening of its core pipeline competitiveness.
Conclusion
Innovative drug R&D is inherently characterized by high investment, high risk, and high return. The courage to proactively "subtract" and focus on the core precisely reflects a pharmaceutical company's strategic resolve and rational judgment. BeiGene's pipeline adjustment not only clears non-core obstacles for its own high-quality development and optimizes resource allocation but also points the way for the transformation of China's innovative drug industry. In the second half of the innovation era, the era of blind expansion and chasing pipeline numbers is completely over. Only by focusing on core areas, insisting on differentiated innovation, and strictly controlling R&D risk can a company stand firm in global market competition. We look forward to BeiGene, after this strategic adjustment, continuing to focus on innovation and deepen its core strengths, bringing more clinically valuable innovative drugs to patients worldwide and driving high-quality development of China's innovative drug industry.